DE112010002253T5 - Mittel und Verfahren zur Diagnostizierung von Prostatakarzinomen - Google Patents

Mittel und Verfahren zur Diagnostizierung von Prostatakarzinomen Download PDF

Info

Publication number
DE112010002253T5
DE112010002253T5 DE112010002253T DE112010002253T DE112010002253T5 DE 112010002253 T5 DE112010002253 T5 DE 112010002253T5 DE 112010002253 T DE112010002253 T DE 112010002253T DE 112010002253 T DE112010002253 T DE 112010002253T DE 112010002253 T5 DE112010002253 T5 DE 112010002253T5
Authority
DE
Germany
Prior art keywords
acid
phosphatidylcholine
metid
metabolite
cis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE112010002253T
Other languages
German (de)
English (en)
Inventor
Beate Kamlage
Edgar Leibold
Glen Kristiansen
Michael Lein
Bianca Bethan
Klaus Jung
Regina Reszka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charite Universitaetsmedizin Berlin
Metanomics Health GmbH
Original Assignee
Charite Universitaetsmedizin Berlin
Metanomics Health GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charite Universitaetsmedizin Berlin, Metanomics Health GmbH filed Critical Charite Universitaetsmedizin Berlin
Publication of DE112010002253T5 publication Critical patent/DE112010002253T5/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
DE112010002253T 2009-06-04 2010-06-02 Mittel und Verfahren zur Diagnostizierung von Prostatakarzinomen Withdrawn DE112010002253T5 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09161956.9 2009-06-04
EP09161956 2009-06-04
PCT/EP2010/057680 WO2010139711A1 (en) 2009-06-04 2010-06-02 Means and methods for diagnosing prostate carcinomas

Publications (1)

Publication Number Publication Date
DE112010002253T5 true DE112010002253T5 (de) 2013-01-03

Family

ID=42320338

Family Applications (1)

Application Number Title Priority Date Filing Date
DE112010002253T Withdrawn DE112010002253T5 (de) 2009-06-04 2010-06-02 Mittel und Verfahren zur Diagnostizierung von Prostatakarzinomen

Country Status (9)

Country Link
US (1) US20120122243A1 (https=)
EP (3) EP3296743A1 (https=)
JP (2) JP5933432B2 (https=)
CN (1) CN102483416A (https=)
CA (1) CA2764049A1 (https=)
DE (1) DE112010002253T5 (https=)
ES (1) ES2516866T3 (https=)
PL (1) PL2438445T3 (https=)
WO (1) WO2010139711A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5754137B2 (ja) 2008-06-20 2015-07-29 味の素株式会社 前立腺癌の評価方法、前立腺癌評価装置、前立腺癌評価方法、前立腺癌評価プログラム、記録媒体、前立腺癌評価システム、および情報通信端末装置
EP2529235B1 (en) 2010-01-29 2019-03-06 Metanomics GmbH Means and methods for diagnosing heart failure in a subject
MY193914A (en) 2012-03-05 2022-11-01 Oy Arctic Partners Ab Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
EP2904397B1 (en) 2012-10-02 2018-07-18 Metanomics Health GmbH Means and methods for diagnosing recurrence of prostate cancer after prostatectomy
JP2014169955A (ja) * 2013-03-05 2014-09-18 Seiko Epson Corp 分析装置、分析方法、これらに用いる光学素子および電子機器、並びに光学素子の設計方法
JP6201369B2 (ja) * 2013-03-28 2017-09-27 セイコーエプソン株式会社 検出装置及び電子機器
ES2534732B1 (es) * 2013-08-05 2016-04-21 Servicio Andaluz De Salud Método de clasificación, diagnóstico y seguimiento de individuos con riesgo de padecer cáncer de pulmón mediante el análisis de sudor
JP6222629B2 (ja) * 2013-08-29 2017-11-01 花王株式会社 排尿障害のバイオマーカー
JP2015055482A (ja) * 2013-09-10 2015-03-23 セイコーエプソン株式会社 分析装置、分析方法、これらに用いる光学素子及び電子機器
KR101838133B1 (ko) 2013-10-04 2018-03-14 주식회사 씨스퀘어 사르코신 대사산물 중 포름알데히드를 이용한 전립선암 진단 시험지, 그 제조 방법 및 이를 이용한 전립선암 진단에 필요한 정보를 제공하는 방법
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
US10274496B2 (en) 2014-01-17 2019-04-30 University Of Washington Biomarkers for detecting and monitoring colon cancer
CN106415274A (zh) * 2014-03-26 2017-02-15 梅坦诺米克斯保健有限公司 基于代谢物组的血液样本质量的测定方法和手段
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
DK3123381T3 (da) * 2014-03-28 2023-11-27 Opko Diagnostics Llc Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer
JP5796863B1 (ja) * 2014-10-31 2015-10-21 節郎 山田 腫瘍検査用組成物及び腫瘍検査用試験紙
CN104614462B (zh) * 2015-02-11 2016-09-14 中国人民解放军第四军医大学 一种高原肺水肿诊断标志物及其应用和诊断试剂盒
WO2016160545A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
EP3229026A1 (en) * 2016-04-06 2017-10-11 Universite De Bordeaux Biomarkers for the diagnosis of inflammation-related diseases
WO2017210097A1 (en) * 2016-06-02 2017-12-07 Metabolon, Inc. Mass spectrometry method for detection and quantitation of metabolites
WO2018181759A1 (ja) 2017-03-31 2018-10-04 学校法人慶應義塾 併用抗がん剤の感受性の判定マーカー
CN107589196B (zh) * 2017-11-02 2019-09-20 浙江高美生物科技有限公司 一种预示肺癌脑转移的小分子标志物及在诊断方面的应用
CN108362804B (zh) * 2018-02-27 2019-01-29 山东英盛生物技术有限公司 一种检测血液样品中dha含量的方法及试剂盒
CA3154765A1 (en) * 2019-10-17 2021-04-22 Rashid Ahmed M. BUX Method of diagnosing early-stage non-small cell lung cancer
CN110749732B (zh) * 2019-11-27 2021-10-15 中南大学 诊断多发性骨髓瘤的血液代谢物标志物及应用
WO2021213494A1 (en) * 2020-04-23 2021-10-28 YatHing Biotechnology Company Limited Methods related to the diagnosis of prostate cancer
CN111721751A (zh) * 2020-06-30 2020-09-29 四川大学华西医院 一种检测结直肠恶性肿瘤的装置
JP2023533959A (ja) * 2020-07-08 2023-08-07 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム 前立腺がんの検出及び治療方法
CN111999404A (zh) * 2020-08-14 2020-11-27 中元伯瑞生物科技(珠海横琴)有限公司 神经酸在制备甲状腺恶性肿瘤的检测试剂中的应用
CN112748195A (zh) * 2020-12-23 2021-05-04 沈阳农业大学 一种利用gc-nci-ms对脂肪酸、氨基酸和多官能团有机酸同时检测的方法
CN112630363A (zh) * 2020-12-31 2021-04-09 四川大学华西医院 一种MXene生物响应特性代谢组学分析方法
CN114527222B (zh) * 2022-02-22 2024-08-06 广州市番禺区中心医院 前列腺癌相关标志物及其应用
EP4581369A1 (en) * 2022-09-02 2025-07-09 Baker Heart and Diabetes Institute Prognostic markers
KR20260041912A (ko) * 2023-09-05 2026-03-27 내셔널 타이완 유니버시티 전립선암용 바이오마커
CN118091155B (zh) * 2024-02-29 2025-02-18 汕头大学医学院第二附属医院 大肠癌代谢标志物及其在诊断大肠癌中的应用
CN118604356A (zh) * 2024-06-06 2024-09-06 温州医科大学 用于前列腺癌风险分层的无创诊断生物标志物组合及其应用
CN119269471B (zh) * 2024-09-19 2026-03-20 青岛大学 基于拉曼光谱的肿瘤细胞转移能力检测方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540884A (en) 1982-12-29 1985-09-10 Finnigan Corporation Method of mass analyzing a sample by use of a quadrupole ion trap
US5397894A (en) 1993-05-28 1995-03-14 Varian Associates, Inc. Method of high mass resolution scanning of an ion trap mass spectrometer
WO2003073464A1 (de) 2002-02-28 2003-09-04 Metanomics Gmbh & Co. Kgaa Massenspektrometrisches verfahren zur analyse von substanzgemischen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006098192A1 (ja) * 2005-03-16 2006-09-21 Ajinomoto Co., Inc. 生体状態評価装置、生体状態評価方法、生体状態評価システム、生体状態評価プログラム、評価関数作成装置、評価関数作成方法、評価関数作成プログラムおよび記録媒体
US20070231822A1 (en) * 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer
EP2369346B1 (en) * 2006-03-24 2014-08-27 Metanomics GmbH Method for diagnosing diabetes type II
WO2007109881A1 (en) * 2006-03-24 2007-10-04 Phenomenome Discoveries Inc. Biomarkers useful for diagnosing prostate cancer, and methods thereof
US20090075284A1 (en) * 2006-09-19 2009-03-19 The Regents Of The University Of Michigan Metabolomic profiling of prostate cancer
JP5297379B2 (ja) * 2006-09-19 2013-09-25 メタボロン、インコーポレイテッド 前立腺癌のバイオマーカー及びそれを使用する方法
JP5406187B2 (ja) * 2007-08-16 2014-02-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌の代謝プロファイリング法
US7989630B2 (en) * 2008-04-30 2011-08-02 National Institutes Of Health Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Radiotracers for imaging P-glycoprotein function
WO2009151967A1 (en) * 2008-05-28 2009-12-17 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540884A (en) 1982-12-29 1985-09-10 Finnigan Corporation Method of mass analyzing a sample by use of a quadrupole ion trap
US5397894A (en) 1993-05-28 1995-03-14 Varian Associates, Inc. Method of high mass resolution scanning of an ion trap mass spectrometer
WO2003073464A1 (de) 2002-02-28 2003-09-04 Metanomics Gmbh & Co. Kgaa Massenspektrometrisches verfahren zur analyse von substanzgemischen

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
Andriole GL et al. 2009 N. Engl. J. Med., 26. März; 360(13): 1310-1319
Ascorbinsäure Winnie Lee, Susan M. Roberts und Robert F. Labbe; Clinical Chemistry 43: 154-157, 1997
BN La Du, RR Howell, PJ Michael und EK Sober; Pediatrics, Jan 1963, 39-46, Band 31, Nr. 1
Crawford ED 2005, Lancet 365: 1447-1449
Dowdy und Wearden, Statistics for Research, John Wiley & Sons, New York 1983
Hubert A. Carchon und Jaak Jaeken; Clinical Chemistry 47: 1319-1321, 2001
J. J. Thiele, H. J. Freisleben, J. Fuchs und F. R. Ochsendorf; Human Reproduction, Bd. 10, Nr. 1, S. 110-115, 1995
Kyaw A; Clin Chim Acta. 1978 Juni; 86(2): 153-7
Mannose Pitkanen E, Pitkanen O, Uotila L.; Eur J Clin Chem Clin Biochem. 1997 Okt; 35(10): 761-6
Niessen, Journal of Chromatography A, 703, 1995: 37-57
Schröder FH et al., 2009; N. Engl. J. Med., 26. März; 360(13): 1320-1328
Serkova et al 2008; (The Prostate 68: 620-628)
Spratlin 2009, Clin Cancer Res 15(2): 431-440
Sreekumar 2009, Nature 457(12): 910-914
Sumi T, Umeda Y, Kishi Y, Takahashi K, Kakimoto F.; Clin Chim Acta. 1976 Dec 1; 73(2): 233-9
Wilson SS, Crawford ED 2004, Clin. Prostate Cancer 3: 21-25
Yamada et al [21]

Also Published As

Publication number Publication date
EP2438445B1 (en) 2014-07-16
JP6427137B2 (ja) 2018-11-21
JP2016153808A (ja) 2016-08-25
ES2516866T3 (es) 2014-10-31
JP5933432B2 (ja) 2016-06-08
WO2010139711A1 (en) 2010-12-09
JP2012529021A (ja) 2012-11-15
EP2804001B1 (en) 2017-08-09
CA2764049A1 (en) 2010-12-09
US20120122243A1 (en) 2012-05-17
PL2438445T3 (pl) 2014-12-31
EP2804001A2 (en) 2014-11-19
EP2804001A3 (en) 2015-01-14
EP3296743A1 (en) 2018-03-21
CN102483416A (zh) 2012-05-30
EP2438445A1 (en) 2012-04-11

Similar Documents

Publication Publication Date Title
DE112010002253T5 (de) Mittel und Verfahren zur Diagnostizierung von Prostatakarzinomen
US10393762B2 (en) Means and methods for diagnosing heart failure in a subject
EP2863227B1 (en) Means and methods for metabolic differentiation of non-alcoholic steatohepatitis from liver disease
AU2009259540B2 (en) Means and methods for assessing liver toxicity
US10436798B2 (en) Means and methods for diagnosing and monitoring heart failure in a subject
JP5829609B2 (ja) 甲状腺疾患を診断するための手段および方法
US20130140452A1 (en) Means and methods for diagnosing pancreatic cancer in a subject
EP2330423A1 (en) Means and method for diagnosing diabetes
DE112010004626T5 (de) Mittel und Verfahren zur Diagnose von multipler Sklerose
DE112014000822T5 (de) Mittel und Verfahren zur Beurteilung der Qualität einer biologischen Probe
DE112009001301T5 (de) Mittel und Verfahren zur Beurteilung einer erhöhten Peroxisomenproliferation
ES2686542T3 (es) Medios y procedimientos para determinar una cantidad normalizada de aclaramiento de un biomarcador de enfermedad metabólica en una muestra
AU2010281748B9 (en) Means and methods for diagnosing thyroid disorders
ES2734810T3 (es) Uso de SM_Esfingomielina (D18:1, C16:0) como un marcador para insuficiencia cardiaca
EQUALLY Systemic Alterations in the Metabolome of Diabetic NOD Mice Delineate Increased Oxidative Stress Accompanied by Reduced Inflammation and Hypertriglyceremia 2

Legal Events

Date Code Title Description
R083 Amendment of/additions to inventor(s)
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee